LGC Mikromol™’s Post

From biomarkers to organ-on-a-chip models, new tools are transforming how we predict toxicity and drug–drug interaction (DDI). ⬇️Download the full white paper for practical guidance aligned with ICH M12: https://ow.ly/xvxr50X6XeS #DrugDevelopment #DDI #PBPK #ICHM12

Tissue Cross-Reactivity assays are a critical part of the drug development process. Get the latest insights in our whitepaper! Download now 👉 https://lnkd.in/eHQ_6SUY #drugdevelopment #lifesciences #cellularpathology #digitalpathology #tcr #whitepaper #drugdiscovery

🆕White Paper on GPCR Signaling Bias launched! The #WhitePaper describes the nuances in #signalingbias & it’s implications in therapeutic profiles of drugs. Expertly written by Terry Kenakin in collaboration with Eurofins DiscoverX, this is a must-read for all #GPCR enthusiasts & GPCR drug discoverers. Key Learnings: ·      Signaling bias & its quantification ·      Influence of bias signaling on therapeutic profiles ·      Use of pharmacological tools to quantitate systemic comparison of biased agonism Access GPCR Signaling Bias White Paper, https://lnkd.in/dSeeUrXa

🫁 Case Study: Quantitative imaging in the Fibroblast-to-Myofibroblast Transition (FMT) assay The challenge❓ To evaluate three anti-fibrotic drug candidates in an FMT assay. We used high content imaging (HCI) to assess their effects on two disease-relevant markers This high-throughput study generated over 1,000 data points and was completed in just over a month. Read the full case study here 👉 https://lnkd.in/eHJ5WSFT #Newcells #Fibroblasts #LungModels #HighContentImaging #Pharma

The Neurofilament Surveillance Project (NSP) is a precompetitive, observational study that tracks how blood biomarkers such as NfL change over time. Sponsored by The Bluefield Project and supported by 10 pharma/biotech companies and 3 foundations, the NSP includes members of families with variants in 𝘎𝘙𝘕, 𝘔𝘈𝘗𝘛, or 𝘊9𝘰𝘳𝘧72. Details ➡️ https://lnkd.in/gTPtyFK8 #FTDAwareness #FTDResearch #CureFTD #EndFTD #FTDAwarenessWeek #ALLFTD #FTDAwarenessWeek2025

🚀 Breaking the Cost Barrier in CAR-T & CAR-NK Development 10x cost reduction in #GMP_Lentivirus_manufacturing, down to just $100 per CAR-T dose LVV. A breakthrough that reshapes the economics of gene-modified cell therapy and speeds access to patients in need. 🔑 Why choose #uBriGene as your CDMO partner? As a trusted ally for CAR-TCR development, our #LVV_Turbo platform and GMP-ready infrastructure deliver: 1️⃣ Proprietary 293TH suspension cell line 2️⃣ In-stock GMP-grade LVV packaging plasmids (DMFs on file with FDA) 3️⃣ Streamlined, regulatory-compliant GMP processes 4️⃣ A team with deep expertise in GMP vector production and release With a mature 3rd-generation GMP lentivirus platform, access to qualified raw materials, and end-to-end support, we’re committed to lowering barriers and accelerating next-generation #CAR_T and #CAR_NK therapies. 👉 Learn more: https://lnkd.in/gwRzPkSg 📩 Request a quote: https://lnkd.in/gE29p_BB

“The world of degrader drug discovery is rapidly expanding and evolving, providing new promise for disease targets classically considered undruggable.”   In our recent article in Drug Development & Delivery, we explore how our drug discovery platforms, SITESEEKER® and GlueSEEKER®, are enabling the development of both heterobifunctional degraders (PROTACs) and molecular glues, harnessing novel E3 ligases to expand the druggable space. Read the full article here: https://lnkd.in/ev_ndzjh #DegraderTherapeutics #PROTACs #DrugDiscovery

PhoreMost’s SITESEEKER technology com­bines the benefits of high-throughput screening typically associated with genetic perturbation screens with highly translat­able output enabling the development of small molecule degraders

Drug development MOA costs from $2M in 2 years, to down to $60K in 6 months: Method of action (MOA) studies are a critical step in the drug development pipeline. They typically take two years and cost $2,000,000. Using AI, we can now run an entire MOA on a novel antibiotic in six months for $60,000. The biotech market still hasn't priced this in yet: 2 two-order-of-magnitude reduction in the cost of this step of the drug development pipeline. What a time to be alive!